Clinical Trial Update: Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study update evaluating safety and pharmacokinetics of ODM-204 in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ODM-204

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED